Paper Excellence donations lead to $250,000 in support of wildfire rebuilding efforts

January-September 2021 compared with January-September 2020 *Net sales amounted to SEK 14,059m (13,818). The increase was primarily attributable to higher selling prices in all product areas. The discontinued publication paper operations (see page 5) and the divestment of Wood Supply UK (see page 7) had a negative impact on sales. Excluding these effects, net sales increased by 26%. *EBITDA increased 106% to SEK 6,303m (3,0631). The increase was mainly attributable to higher selling prices in all product areas and a stable, low cost level. EBITDA margin increased with 23 percentage points (of which 8 resulted from the discontinuation of publication paper operations and the divestment of Wood Supply UK) and was 44.8% (22.11). *Operating profit increased to SEK 5,226m (1,8531) *Operating cash flow amounted to SEK 3,453m (1,731)

Mondi delivered strongly in the first quarter of 2022. Demand was good across the business, supported by our broad range of innovative, sustainable packaging and paper solutions, product quality and customer service. Higher average selling prices more than offset continued cost pressures. Underlying EBITDA for the first quarter was €574 million, up 63% compared to the prior year period (Q1 2021: €353 million) and up 41% on a sequential basis (Q4 2021: €406 million). In the current context, the Group believes it is appropriate to report that excluding the Russian operations, underlying EBITDA for the first quarter was approximately €460 million, up around 70% compared to the prior year period. This performance is testament to the continued dedication of our people, our strong customer relationships and the strength of our integrated business model.

FibDex® wound dressing – made from nanofibrillar cellulose by UPM Biomedicals – has taken a significant step in its path to market, as leading medical device distributor Steripolar Oy now sells the product in Finland. FibDex is the first clinical product of renowned forest-based bioindustry company UPM and shows promising signs for future developments, such as cell therapy. ”We are excited to offer this Finnish product, made from Finnish raw material, first in the world to Finnish healthcare professionals and patients,” said Johana Kuncova-Kallio, Director of UPM Biomedicals. “Nanofibrillar cellulose has proven its potential both in the development of cell therapies and in clinical applications, and we are committed to further innovation.” Kaj Dahlström, CEO of Steripolar, added: “We were attracted to the ingenuity of FibDex. We are always looking for products and solutions that offer diverse and pain-free healing, while minimizing damage to the environment.”